These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18369620)

  • 1. Targeting activity of a TCR/IL-2 fusion protein against established tumors.
    Wen J; Zhu X; Liu B; You L; Kong L; Lee HI; Han KP; Wong JL; Rhode PR; Wong HC
    Cancer Immunol Immunother; 2008 Dec; 57(12):1781-94. PubMed ID: 18369620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein.
    Belmont HJ; Price-Schiavi S; Liu B; Card KF; Lee HI; Han KP; Wen J; Tang S; Zhu X; Merrill J; Chavillaz PA; Wong JL; Rhode PR; Wong HC
    Clin Immunol; 2006 Oct; 121(1):29-39. PubMed ID: 16807113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
    Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
    von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
    Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
    Lo AS; Ma Q; Liu DL; Junghans RP
    Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.
    Fishman MN; Thompson JA; Pennock GK; Gonzalez R; Diez LM; Daud AI; Weber JS; Huang BY; Tang S; Rhode PR; Wong HC
    Clin Cancer Res; 2011 Dec; 17(24):7765-75. PubMed ID: 21994418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.
    Gubbels JA; Gadbaw B; Buhtoiarov IN; Horibata S; Kapur AK; Patel D; Hank JA; Gillies SD; Sondel PM; Patankar MS; Connor J
    Cancer Immunol Immunother; 2011 Dec; 60(12):1789-800. PubMed ID: 21792658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity.
    Card KF; Price-Schiavi SA; Liu B; Thomson E; Nieves E; Belmont H; Builes J; Jiao JA; Hernandez J; Weidanz J; Sherman L; Francis JL; Amirkhosravi A; Wong HC
    Cancer Immunol Immunother; 2004 Apr; 53(4):345-57. PubMed ID: 14610621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human IL18-IL2 fusion protein as a potential antitumor reagent by enhancing NK cell cytotoxicity and IFN-γ production.
    Du G; Ye L; Zhang G; Dong Q; Liu K; Tian J
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1727-36. PubMed ID: 22699929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
    Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells.
    Jounaidi Y; Cotten JF; Miller KW; Forman SA
    Cancer Res; 2017 Nov; 77(21):5938-5951. PubMed ID: 28916655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
    Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
    Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of tumor-targeted IL2 in LTalpha(-/-) mice depends on conditioned T cells.
    Schrama D; Voigt H; Eggert AO; Xiang R; Reisfeld RA; Becker JC
    Cancer Immunol Immunother; 2006 Jul; 55(7):861-6. PubMed ID: 16158274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell-cell interactions.
    Wen Q; Xiong W; He J; Zhang S; Du X; Liu S; Wang J; Zhou M; Ma L
    J Transl Med; 2016 Feb; 14():41. PubMed ID: 26850448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R.
    Harvill ET; Morrison SL
    Immunotechnology; 1995 Aug; 1(2):95-105. PubMed ID: 9373338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
    Hu Z; Xia J; Fan W; Wargo J; Yang YG
    Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral immunocytokine treatment results in enhanced antitumor effects.
    Johnson EE; Lum HD; Rakhmilevich AL; Schmidt BE; Furlong M; Buhtoiarov IN; Hank JA; Raubitschek A; Colcher D; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Immunol Immunother; 2008 Dec; 57(12):1891-902. PubMed ID: 18438664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
    Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
    J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.